On Oct. 31, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had notified the Company that additional time was required to complete its assessment of Modernaﾒs Emergency Use Authorization (EUA) request for the use of the Moderna COVID-19 vaccine (mRNA-1273) at the 100 ﾵg dose level in adolescents 12 to 17 years of age.